Pace, Anna
Barber, Mark
Ziplow, Jason
Hranilovich, Jennifer A.
Kaiser, Eric A.
Article History
Accepted: 26 October 2021
First Online: 15 December 2021
Declarations
:
: JH, AP, MB, JZ: no conflict. EAK has received royalties from patents in association with Alder Biopharmaceuticals related to anti-CGRP monoclonal antibodies for the treatment of migraine and photophobia. EAK has received investigator-driven grant funding from Amgen, which manufactures an anti-CGRP monoclonal antibody for the treatment of migraine.
: This article does not contain any studies with human and animal subjects performed by any of the authors.